Journal of Cardiothoracic and Vascular Anesthesia 1997-02-01

Effects of lidoflazine on left ventricular function in patients.

S G De Hert, I E Rodrigus, L R Haenen, P W Ten Broecke, C J Boeckxstaens, T C Gillebert

Index: J. Cardiothorac. Vasc. Anesth. 11(1) , 42-8, (1997)

Full Text: HTML

Abstract

The present study evaluated the effects of the nucleoside transport inhibitor, lidoflazine, at a dose of 1 mg/kg, on left ventricular function.Patients were randomly assigned to receive either lidoflazine or saline in a double-blind manner.A university hospital.The study was performed in 32 patients scheduled for elective coronary artery bypass surgery.Left ventricular pressures were measured with fluid-filled catheters. Data were digitally recorded during pressure elevation induced by tilt-up of the legs. Transgastric short-axis echocardiographic views of the left ventricle were simultaneously recorded on videotape. Systolic function was evaluated with the slope (Ees, mmHg/mL) of the systolic pressure-volume relationship. Diastolic function was evaluated with the chamber stiffness constant (Kc, mmHg/mL) of the diastolic pressure-volume relationship. Cardiac function was assessed at baseline and after administration of either lidoflazine (group A [n = 16]) or placebo (group B [n = 16]). Data were compared using two-factor analysis of variance.At baseline, diastolic and systolic function were comparable in both groups. Lidoflazine increased Kc from 0.079 +/- 0.015 to 0.125 +/- 0.017 mmHg/mL and decreased Ees from 2.481 +/- 0.213 to 1.217 +/- 0.211 mmHg/mL (p = 0.009 and p = 0.004, respectively). None of these changes occurred when placebo was administered.Administration of lidoflazine before the start of cardiopulmonary bypass impaired left ventricular systolic function but also increased diastolic stiffness.


Related Compounds

  • Lidoflazine

Related Articles:

Protective effects of the lazaroid U74500A and lidoflazine on liver preservation with UW solution.

1993-01-01

[Transpl. Int. 6(5) , 281-4, (1993)]

Simpson's paradox and clinical trials: what you find is not necessarily what you prove.

1992-12-01

[Ann. Emerg. Med. 21(12) , 1480-2, (1992)]

1,4-Dihydropyridines bearing a pharmacophoric fragment of lidoflazine.

1996-10-01

[Bioorg. Med. Chem. 4(10) , 1629-35, (1996)]

The pathophysiology of angina pectoris and the effect of lidoflazine.

1982-01-01

[Circulation 65(1 Pt 2) , I27-32, (1982)]

Lidoflazine and myocardial protection.

1995-05-01

[J. Thorac. Cardiovasc. Surg. 109(5) , 1013-4; discussion 1015, (1995)]

More Articles...